#United States #Detroit #Karmanos Cancer Institute #Khalil Choucair #Thoracic Oncology

Karmanos Cancer Institute Welcomes Dr. Khalil Choucair

The Barbara Ann Karmanos Cancer Institute is excited to announce the addition of Dr. Khalil Choucair, M.D., MSc, to its Thoracic Oncology and Phase I Clinical Trials teams. Starting his role at the Detroit location, Dr. Choucair brings extensive expertise and a fresh perspective to the treatment of chest-related cancers.

A New Chapter in Thoracic Oncology

Dr. Choucair specialized in thoracic cancers, focusing on conditions such as lung cancer, esophageal cancer, and mesothelioma. His academic journey began at the American University of Beirut, followed by residency at the University of Kansas, where he became a chief resident. He later pursued a research fellowship in precision oncology at the Eleanor N. Dana Cancer Center, further enhancing his knowledge in this vital field.

After completing his hematology and oncology fellowship at Karmanos—where he served as chief fellow—Dr. Choucair joined the institute with a wealth of experience. His background includes active participation in clinical trials, concentrating on promising new therapies that may one day redefine standard treatment protocols for cancer patients.

Committed to Patient Care and Research

Excited about his new role, Dr. Choucair expressed, "Karmanos is an esteemed institution where daily research is conducted to discover cutting-edge cancer therapies that can transform patient treatment. I am honored to be part of such a prestigious organization and eager to contribute to advancements that will help patients not only in Michigan but around the globe."

As a key member of the Phase I team, Dr. Choucair investigates and pioneers research into new cancer drugs and therapy combinations that show promise in laboratory settings. His goal is to aid the development of new treatment options that will potentially become the benchmark in oncological care.

Collaboration and Leadership

Dr. Choucair has already made a significant impact by co-directing the annual Lung Cancer Symposium, collaborating with fellow oncologists to bring together experts from various fields to discuss the latest advancements in lung cancer treatment. His commitment to education is clear; he has additionally contributed to the Cancer Research Office at Karmanos since 2023, guiding future specialists and researchers.

As a clinical assistant professor at Wayne State University School of Medicine, Dr. Choucair’s role is twofold: engaging in patient care while nurturing the next generation of cancer care professionals. His work is backed by a prolific portfolio of over 30 peer-reviewed publications, showcasing his dedication to advancing cancer research and patient care.

The Vision for Karmanos

Founded with the vision of creating a world free from cancer, the Karmanos Cancer Institute stands out as a pioneer in cancer research, education, and transformative patient care. Housed in downtown Detroit for over 75 years, the institute is recognized as a comprehensive cancer center by the National Cancer Institute.

For those seeking more information about Dr. Choucair or to schedule an appointment, they can connect directly with the Karmanos Cancer Institute through their website or via phone at 1-800-KARMANOS. As part of McLaren Health Care, the Karmanos Cancer Institute continues leading the fight against cancer, striving to develop innovative therapies that enhance treatment outcomes and patient experiences.

In conclusion, Dr. Khalil Choucair’s entry to the Karmanos has invigorated the Thoracic Oncology department, promising progress and hope for many battling thoracic cancers. His expertise and passion will certainly contribute to innovative solutions and improved patient outcomes in the field of oncology.